Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Hirva Mamdani(Wayne State University), Shadia I. Jalal(Indiana University Health), Sandro Matosevic(Purdue University West Lafayette), Ahmed Bilal Khalid(Indiana University School of Medicine), Gregory A. Durm(Indiana University Melvin and Bren Simon Comprehensive Cancer Center)
Cited by 373
Related Papers
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
|Journal of the National Comprehensive Cancer Network|2023|480
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125